Mangalodayam Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
as on 21-05-2024
- Paid Up Capital ₹ 0.80 M
as on 21-05-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 7.47%
(FY 2022)
- Profit 66.23%
(FY 2022)
- Ebitda 18.88%
(FY 2022)
- Net Worth 13.31%
(FY 2022)
- Total Assets -8.78%
(FY 2022)
About Mangalodayam Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Aboobacker Haje, Abdul Veettil, Puthiya Sageer, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24239KL2006PTC019553
- Company No.
019553
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2006
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Malappuram, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Mangalodayam Pharmaceuticals Private Limited offer?
Mangalodayam Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic Herbal Syrups & Tonics, Herbal Cough Syrup, Pharmaceutical Syrup, Dry Syrups, Ayurvedic Joint Pain Relief Medicine, Ayurvedic Joint Pain Syrup.
Who are the key members and board of directors at Mangalodayam Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aboobacker Haje  | Director | 27-Jun-2006 | Current |
| Abdul Veettil | Director | 27-Jun-2006 | Current |
| Puthiya Sageer | Director | 27-Jun-2006 | Current |
| Puthiya Asaraf | Director | 27-Jun-2006 | Current |
| Mohammed Salahudheen | Director | 27-Jun-2006 | Current |
| Puthiyaveettil Mohamed | Director | 27-Jun-2006 | Current |
Financial Performance of Mangalodayam Pharmaceuticals.
Mangalodayam Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.47% increase. The company also saw a substantial improvement in profitability, with a 66.23% increase in profit. The company's net worth Soared by an impressive increase of 13.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mangalodayam Pharmaceuticals?
In 2017, Mangalodayam Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mangalodayam Pharmaceuticals?
Unlock and access historical data on people associated with Mangalodayam Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mangalodayam Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mangalodayam Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
